本帖最后由 老马 于 2013-3-13 13:43 编辑 * E. e O" y( J
: n4 x2 h8 V3 X/ E1 ?% ~3 \1 x4 y7 Q
健择（吉西他滨）+顺铂+阿瓦斯汀9 F. o @8 w$ n0 n: w E; W
Gemzar +Cisplatin + Avastin2 p! i. B1 W, z
http://annonc.oxfordjournals.org/content/21/9/1804.full8 h- E! ]4 J! j; I6 f6 E
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) # v# K: ?; k* ]2 K( b6 _, J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 i0 D' L! Z' r# V! jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 8 @5 ?) J% d( D* w, n; H
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 852)
. r/ A" }, X! ?+ S
华为网盘附件：$ U) n( o& a) `$ f3 [$ k" X- V
【华为网盘】ava.JPG
; i4 H' n' _; y2 {" J |
显身卡
